EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study

Teppei Hagino iD, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Dermatitis® · 01.01.2026 · 37 (1) · 84-90

DOI: 10.1089/derm.2024.0538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatitis®, online erschienen am 11.02.2025. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD), but its effectiveness on different anatomical sites and clinical signs remains unclear.

Objective

To assess the effectiveness of tralokinumab on different anatomical sites and clinical signs of AD.

Methods

This study included 129 moderate-to-severe AD patients treated with tralokinumab for 36 weeks. Eczema Area and Severity Index (EASI) scores were analyzed on four anatomical sites (head/neck, trunk, upper, and lower limbs) and four clinical signs (erythema, edema/papulation, excoriation, and lichenification) at weeks 0, 4, 12, 24, and 36.

Results

Tralokinumab consistently reduced EASI scores on 4 anatomical sites and 4 clinical signs. The magnitude of decreasing EASI appeared highest on lower limbs while the achievement rates of EASI 75 at week 36 on 4 anatomical sites were mostly similar (72.6–77.6%). The magnitude of decreasing EASI and achieving EASI 75 or 100 appeared highest for excoriation, and the rates of EASI 75 at week 36 for erythema, excoriation, lichenification and edema/papulation were 71.1%, 69.4%, 68.4%, and 60.5%, respectively.

Conclusions

Tralokinumab reduced EASI scores across various anatomical sites and clinical signs in moderate-to-severe AD patients. These findings suggest that tralokinumab may be widely useful for diverse skin manifestations of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, MonoclonalDermatologic AgentsHumansMaleFemaleAdultSeverity of Illness IndexMiddle AgedTreatment OutcomeYoung AdultAdolescentEdema

Substanzen

Antibodies, MonoclonaltralokinumabDermatologic Agents

Autor:innen und Institutionen

  • From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino

Zitieren

APA

Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2026). Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study. Dermatitis®, 37(1), 84-90. https://doi.org/10.1089/derm.2024.0538

Vancouver

Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study. Dermatitis®. 2026;37(1):84-90. doi:10.1089/derm.2024.0538

BibTeX
@article{Hagino2026,
  author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study},
  journal = {Dermatitis®},
  year = {2026},
  volume = {37},
  number = {1},
  pages = {84--90},
  doi = {10.1089/derm.2024.0538}
}
Kostenlos starten →